Form 4 for GILD Gilead Sciences
Accepted 2025-02-13 00:00:00 ET · period of report 2025-02-12 · accession 0001127602-25-004784 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-02-13 | 2025-02-12 | GILD | Dickinson Andrew D | CFO | M - OptEx | $67.27 | +137.7K | 248.9K | +124% | +$9.26M |
| D | 2025-02-13 | 2025-02-12 | GILD | Dickinson Andrew D | CFO | S - Sale+OE | $102.22 | -137.7K | 171.2K | -45% | -$14.07M |
| DM | 2025-02-13 | 2025-02-12 | GILD | Dickinson Andrew D | CFO | M - OptEx | $0.00 | -137.7K | 17.9K | -88% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-12 | M | A | 15,600 | $80.72 | 290,689 | D | — | — | |
| 2 | Common | Common Stock | 2025-02-12 | M | A | 26,175 | $57.92 | 275,089 | D | — | — | |
| 3 | Common | Common Stock | 2025-02-12 | S | D | 137,676 | $102.22 | 171,223 | D | — | — | |
| 4 | Common | Common Stock | 2025-02-12 | M | A | 18,210 | $83.49 | 308,899 | D | — | — | |
| 5 | Common | Common Stock | 2025-02-12 | M | A | 77,691 | $63.91 | 248,914 | D | — | — | |
| 6 | Derivative | Non-qualified Stock Option (Right to Buy) | 2025-02-12 | M | D | 18,210 | $0.00 | 0 | D | $83.49 · — to 2028-02-01 | 18,210 Common Stock | (F2) The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 7 | Derivative | Non-qualified Stock Option (Right to Buy) | 2025-02-12 | M | D | 15,600 | $0.00 | 0 | D | $80.72 · — to 2028-03-10 | 15,600 Common Stock | (F2) The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 8 | Derivative | Non-qualified Stock Option (Right to Buy) | 2025-02-12 | M | D | 26,175 | $0.00 | 78,515 | D | $57.92 · — to 2032-03-10 | 26,175 Common Stock | (F2) The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 9 | Derivative | Non-qualified Stock Option (Right to Buy) | 2025-02-12 | M | D | 77,691 | $0.00 | 17,929 | D | $63.91 · — to 2031-03-10 | 77,691 Common Stock | (F2) The shares subject to the option have a four year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |